| | | Yup, pretty muted reaction, perhaps expected given that the briefing docs were pretty positive. There was some risk for this AdCom, but not that much. Will take analyst support to move it much farther. Given the cash cushion, it may not get it: sell side feels no need to curry favor since they won't be asked to help with a raise any time soon. OTOH, this company is about the last man standing in the new drugs for acne space. As I've said about PRTK before, I see limited downside from here, but at best a slow grind up. And that's assuming they execute well. One caveat to their "send patient home earlier on the oral antibiotic" strategy is that some nausea showed up with the oral (at home) version. So even if insurers see the value of that strategy, will the scrips be there?
Cheers, Tuck |
|
